Transforming biomanufacturing using software with Martin Permin

Excited to have a conversation with Martin Permin, Founder and CEO of Invert. The company is on a mission to transform biomanufacturing through advanced software and data analytics. We discuss the founding of Invert, what capabilities they give their customers, and the importance of biomanufacturing to grow biological products like proteins, enzymes, and specialty chemicals. Production from bioreactors allows us to produce important medicines, sustainable materials, biofuels, and other products that will shape our future. However, it's incredibly complex with so many variables to control. A perfect place for software to shine. And where Invert comes in.

Martin started the company in 2021 to help biomanufacturers manage, analyze, and optimize their data. The Invert platform integrates with bioreactors and databases to capture bioprocessing data. It then applies AI and analytics to surface insights and identify process improvements. Just ID’ing ways to improve, or avoiding bad runs, in bioprocessing is a major pain point for companies trying to develop or scale up their manufacturing. Invert makes it seamless to manage these processes across an organization.

Before starting Invert, Martin had an entrepreneurial career with roles at Airbnb and Hive. Then saw an opportunity to bring a modern software solution to the biotech industry. Invert’s features really exemplify this vision. The platform provides tools for planning experiments, monitoring bioprocess runs as they happen, analyzing results across projects, modeling scale-up, and collaborating with partners. It works to eliminate all the manual workflows that hold companies back.

Since launch, Invert has had strong traction within synthetic biology and industrial biotech setting up expansion to biopharma customers. For many, it's become mission-critical for managing their data and enabling team collaboration. In our conversation, Martin talks about how customers use Invert at various stages of their product development. From optimizing algae strains to make renewable chemicals. To developing synthetic meats and helping customers compare runs across sites. Martin also shares his vision for the future of biomanufacturing and software for biotech. Where he paints a picture on how data-driven science can lead to more accessible medicines, foods, and materials.